US Stock-Market - Stock Profile of the Week
Symbol: HTDS
Market: PK
Sector: MEDICAL RESEARCH
The Last time HTDS was at this price level it went from .038 to 10 cents in just a few
days.
Before we begin our profile we have very exciting, breaking news...
Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials
BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases
Incorporated (Pink Sheets:HTDS) announces that Tubercin� has passed the toxicity tests
required to proceed to the live cancer trials. Testing Tubercin� on live Melanoma,
Lung and Breast cancer cells will begin immediately. The President and CEO, Mr. Colm
J. King, met with the spokesperson of the medical team at their offices in Oklahoma
City. Mr. King was advised that the tests were conducted under strict FDA (Federal
Drug Administration) guidelines. Full test results will be available at the corporate
offices as soon as the reports and findings are printed.
"These are the most promising results to date regarding Tubercin� and we're looking
forward to additional positive results in the near future," stated Mr. King. "These
tests prove that Tubercin� is non-toxic and is the first step on the way to human
clinical trials as well as the first positive break-through conducted in the United
States with an independent medical team for Tubercin�."
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD")
holds the international marketing rights, except South Korea, to Tubercin�, a patented
immunostimulant developed for combating Cancer under medical patent (US Patent
6,274,356). The unique properties unlike other cancer products are clearly stated in
the abstract summary of the patent... "A carbohydrate complex, which is a mixture of
low molecular-weight polysaccharides of an arabinomannan structure extracted from
Mycobacterium tuberculosis, is highly effective in treating various cancer patients
without incurring any adverse side effects."
STOCK PROFILE OF THE WEEK
HTDS is now at an emerging and potentially explosive stage. As stated in their press
release, Tubercin is now ready to proceed (after tests conducted under strict FDA
guidelines) to human clinical trials. While they have jumped one very big hurdle,
they are still in the early stages of development and now is a great time for
investors to take heed.
TUBERCIN
Over the past ten years, epoch making anticancer agents have continuously been
introduced, but the mortality of cancer patients have been rising in the U.S. and the
European countries not to mention Japan and Korea. The decisive measure to cope with
cancer is surgery.
When the cancer cells spread throughout a person instead of remaining on the original
spot, the treatment should take into consideration chemotherapy, radiation therapy and
immunotherapy. The drawback of such therapies, however, is they incur damages not only
on cancer cells, but also on the normal cells.
Chemotherapy and radiation therapy are not suitable for application on weakened
patients, especially those above 70. Historically, various forms of immunotherapy have
been performed, falling short of therapeutic expectation. When Bacille calmetteguerin
is used as an active no-specific immunotherapeutic agent, however, the patient's
prognosis turns better through a simulative action on immune system of the cancer
case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from
microbacterium tuberculosis to be used as immunostimulant. This was meant to activate
the T-lymphocyte of the cancer patient to produce lymphokine. This process
strengthened and promoted immuno surveillance activities in deficient state and
alleviated the pain and prolonged the life of cancer patients.
Of late the pharmaceutical industry in advanced countries started to put on the market
so called cancer vaccines (active specific immunotherapy). The vaccines, bacterial
extracts, as adjuvants, with autologous and or allogenic cancer cells to generate
antibodies to cancer cells, facilitating the killer T-cells to recognize and destroy
cancer cells.
The laboratory work to modify autologous or allogenic cancer cells are not ordinary
and simple. When our lab work augments the active specific immunotherapeutic agents,
the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is
its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently,
we focus our effort on the application of Tubercin to AIDS.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN
strengthens a person's own immune system and assists in seeking out and combating
cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost product to
treat cancer patients on an international scale. Salient treatment, through the
administration of TUBERCIN, could positively affect thousands of lives in North
America. In addition, Europe and Asia have millions of lives at risk each year because
of viral diseases such as cancer.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered
to human patients in stages three and four of terminal cancer. There have been no
indications of any adverse side effects in human trials. There has been encouraging
results of patients with TUBERCIN in the last fourteen years. Various forms of cancer
were involved and many of the patients survived.
A review of clinical studies indicate TUBERCIN has no side effects and could possibly
be administered in conjunction with other such modalities for the treatment of cancer
without any adverse effects. The scientific presumption would be the distinct
possibility of a strengthened immunity system and the administration of treatment such
as chemotherapy at the later stages of tumor growth would not be impeded by the
weakened condition of the terminal cancer patient. To this end the Company has been
assisted by outside consultants reviewing the research data and human trials involving
TUBERCIN to see specifically whereby incidents of dual treatment produced favorable
results in terms of moving toward indication of prolongation of the life of the cancer
patient.
There is recognition that morphine is an trusted pain killer, but in totality it
cannot be said that it has no side effects. In the maintaining of patient care, there
is the strong possibility that TUBERCIN could be also considered as a candidate for a
pain management. The Company's scientists describe TUBERCIN as having the high
propensity of deadening the nerve endings in specific areas where cancer has caused
erosion and consequently much pain.
PATENTS
Presently, HTTD has the patent rights for Korea, Japan and the United States. The
Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese
patent was issued on June 12, 1998 (Registration No. 2790447). The United States
patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents
are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and
Spain).
CANCER IN OUR TIME
In the 20th century, the number of cancer patients has been on the rise. Although many
anti-cancer agents were developed and an enormous study on its essence continued, the
mortality by cancer still is on the rise. Mankind may be chronically threatened with
cancer in the 21st century. Nine million new case of cancer occur annually and five
million people die from breast cancer, reports the World Health Organization. Dramatic
rises in life expectancy and change in lifestyle are estimated to increase the number
of new cancer cases to 20 million annually by 2020 and cancer deaths to more than 10
million.
About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer
this year. In the United States, one of every four deaths is attributed to cancer.
Cancer is the second-leading cause of death in the United States. Exceeded only by
heart disease. About 5 million lives have been lost to cancer since 1990 and about 13
million new cases have been diagnosed. In 2000, more then 1.2 million new cancer cases
are expected to be diagnosed. The number of cancer cases will continue to grow,
spurred by the aging population. By 2009, tese patients could total 8.4 million. In
1997, about 6.3 million people worldwide died from some form of cancer, and most major
international cancer agencies expect this number to double by 2022.
Please note that HTDS had absolutley nothing to do with this report and is not a
participant in any way.
No more advertisements: http://doubleopt.biz/optout.html
This report is based on Stock-Market Spotlight's independent analysis but also relies
on information supplied by sources believed to be reliable. This report may not be the
opinion of HTDS management. This report should be considered biased and contains
usually only positive statements regarding the featured company. Stock-Market
Spotlight does not own or will not purchase HTDS common shares in the open market. The
information contained in this report shall not constitute, an offer to sell or
solicitation of any offer to purchase any security. Penny stocks are considered to be
highly speculative and may be unsuitable for all but very aggressive investors. It is
intended for information and entertainment only. Some statements may contain so-called
"forward-looking statements". Many factors could cause actual results to differ.
Investors should consult with their Investment Advisor concerning HTDS. This
newsletter was written and distributed for a 4000 dollar fee paid by a thir
d party HTDS shareholder who is purported to have a large stock position in the
featured company. It is unknown to Stock-Market Spotlight whether this shareholder
intends to sell any or all of his stock position in the featured company. Copyright
2004 Stock-Market Spotlight. All Rights Reserved.
